Strategic Wealth Advisors Group LLC Invests $2.50 Million in Bristol-Myers Squibb Co (BMY) Stock

Strategic Wealth Advisors Group LLC acquired a new stake in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 39,163 shares of the biopharmaceutical company’s stock, valued at approximately $2,496,000.

A number of other large investors have also recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. grew its position in Bristol-Myers Squibb by 7.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 188,137 shares of the biopharmaceutical company’s stock valued at $11,992,000 after acquiring an additional 12,737 shares in the last quarter. Bank of New York Mellon Corp grew its position in Bristol-Myers Squibb by 7.6% in the third quarter. Bank of New York Mellon Corp now owns 18,855,413 shares of the biopharmaceutical company’s stock valued at $1,201,843,000 after acquiring an additional 1,335,290 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in Bristol-Myers Squibb by 5.8% in the third quarter. DekaBank Deutsche Girozentrale now owns 969,352 shares of the biopharmaceutical company’s stock valued at $56,078,000 after acquiring an additional 52,709 shares in the last quarter. Sigma Planning Corp grew its position in Bristol-Myers Squibb by 9.0% in the third quarter. Sigma Planning Corp now owns 34,854 shares of the biopharmaceutical company’s stock valued at $2,222,000 after acquiring an additional 2,877 shares in the last quarter. Finally, Lockheed Martin Investment Management Co. grew its position in Bristol-Myers Squibb by 242.9% in the third quarter. Lockheed Martin Investment Management Co. now owns 96,700 shares of the biopharmaceutical company’s stock valued at $6,164,000 after acquiring an additional 68,500 shares in the last quarter. 69.74% of the stock is owned by institutional investors.

Bristol-Myers Squibb Co (NYSE:BMY) opened at $59.92 on Wednesday. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10. The stock has a market capitalization of $98,070.00, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.30 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the business earned $0.77 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. analysts predict that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.67%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.99%.

BMY has been the subject of several recent research reports. UBS Group reaffirmed a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research report on Monday, October 9th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Finally, Citigroup raised their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $65.11.

In related news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

WARNING: “Strategic Wealth Advisors Group LLC Invests $2.50 Million in Bristol-Myers Squibb Co (BMY) Stock” was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://weekherald.com/2018/01/17/strategic-wealth-advisors-group-llc-invests-2-50-million-in-bristol-myers-squibb-co-bmy-stock.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply